P3 Health Partners (PIII) Q3 2024 earnings summary

Executive summary

• Revenue grew 26% year-over-year to $362.1 million in Q3 2024, driven by a 22% increase in membership and expansion into nine new counties.

• The company faced significant headwinds from elevated Part B medical utilization, higher medical expenses, and $35 million in retroactive adjustments, resulting in an adjusted EBITDA loss of $71 million.

• Net loss attributable to controlling interest was $46.5 million, while overall net loss widened to $102.9 million, reflecting higher medical costs and premium deficiency reserves.

• Strategic initiatives totaling over $130 million are underway to improve EBITDA and cash flow, focusing on contracts, operational discipline, efficiency, and data analytics.

• The company is not immediately pursuing additional capital raises but is exploring options due to ongoing liquidity concerns and substantial doubt about going concern status.

Financial highlights

• Capitated revenue reached $357.7 million; total revenue was $362.1 million for Q3 2024, up 26% year-over-year.

• Medical margin was $0.5 million ($1 PMPM), down from $36.2 million in Q3 2023; adjusted operating expenses were flat year-over-year.

• Adjusted EBITDA loss was $71 million ($184 PMPM), primarily due to $35 million in retroactive adjustments and $5–10 million in elevated medical claims.

• Gross loss for Q3 2024 was $39.8 million, compared to gross profit of $9.1 million in Q3 2023.

• Cash and restricted cash at quarter-end totaled $68.1 million, including a $15 million deposit for the Florida asset sale.

Outlook and guidance

• No formal outlook provided; 2024 guidance was withdrawn due to lower-than-expected risk adjustment, elevated medical costs, and retroactive adjustments.

• Management expects continued operating losses and negative cash flows as the company invests in growth and expands its member base.

• Directional comments indicate 2025 will benefit from $130 million+ in improvement initiatives and decreased utilization due to benefit design changes.

• Adjusted EBITDA loss run rate expected to improve to ~$30 million per quarter annualized, down from Q3's $70 million.

• Completion of the sale of Florida operations is expected in Q4 2024, with a $15 million deposit already received.